Market Place
Sourcing Support
High Court reinstates Injunction stopping sale of Zydus’ Sigrima
29 Oct 2024 //
EXPRESSPHARMA
Primary Endpoint Met In Ph 3 Study Of Perjeta Biosimilar HLX11
30 Sep 2024 //
PRESS RELEASE
Zydus and Dr. Reddy`s announce agreement for marketing of Pertuzumab biosimilar
29 Jun 2024 //
PRESS RELEASE
Henlius’ Pertuzumab Biosimilar Shows Similar PK Profile to Reference Product
02 Jul 2022 //
CENTERFORBIOSIMILARS
Roche launches antibody drug for breast cancer in India
13 May 2022 //
ECONOMIC TIMES
Chugai gets Japanese approval for Perjeta, Herceptin in HER-2 positive CC
29 Mar 2022 //
PHARMABIZ
BMS` Opdivo hits more approvable goal in early NSCLC
09 Nov 2021 //
SEEKINGALPHA
UK cancer centre to offer breast cancer treatment at home
26 Apr 2021 //
PHARMATIMES
Meeting highlights from the Committee for Medicinal Products for Human Use
13 Nov 2020 //
EMA
Roche wards off Herceptin copycats with Perjeta combo product
01 Jul 2020 //
FIERCE PHARMA
FDA approves Roche’s Phesgo for HER2-positive breast cancer
30 Jun 2020 //
PRESS RELEASE
FDA Approves Breast Cancer Treatment That Can Be Administered
29 Jun 2020 //
PRNEWSWIRE
Seattle Genetics Announces the Approval of TUKYSA™ (tucatinib)
12 May 2020 //
BUSINESSWIRE
Halozyme Announces FDA Has Accepted BLA For Fixed-Dose Subcutaneous Combination
25 Feb 2020 //
PR NEWSWIRE
Genentech`s PERJETA® (pertuzumab) Receives Supplimental Approval in U.S
16 Jan 2020 //
FDA
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
18 Dec 2019 //
PMLIVE
APHINITY six-year results evidence of clinical benefit with Roche’s Perjeta
12 Dec 2019 //
PHARMABIZ
APHINITY six-year results strengthen evidence- Roche’s Perjeta-based regimen
11 Dec 2019 //
PRESS RELEASE
Drugmakers slash prices in China to get on reimbursement list
27 Nov 2019 //
CNBC
Genentech to Present Data for 7 Approved Medicines for Multi Type Breast Cancer
17 Nov 2019 //
BUSINESS WIRE
U.K.Labour Party wants government to build its own manufacturing
25 Sep 2019 //
FIERCE PHARMA
Biosimilars will leave a $10B gap in Roche`s sales: exec
19 Sep 2019 //
FIERCE PHARMA
Biosimilars will leave a $10B gap in Roche`s sales: exec
18 Sep 2019 //
FIERCE PHARMA
Roche’s fixed-dose subcutaneous combination of Perjeta & Herceptin
13 Sep 2019 //
PRESS RELEASE
Roche preps filings for Herceptin/Perjeta combination
13 Sep 2019 //
PMLIVE
Genentech settles fight over cancer drug trade secrets with Taiwan`s JHL
06 Sep 2019 //
FIERCEPHARMA
Chugai seeks new Kadcyla indication in Japan
30 Aug 2019 //
THE PHARMALETTER
Roche`s New Cancer, MS Drugs Pay Off With a Forecast Boost
18 Apr 2019 //
BLOOMBERGQUINT
Roche`s drugs, new and old, team up for major sales
17 Apr 2019 //
FIERCE PHARMA
SMC OK`s four meds for NHS use, including Roche`s Perjeta
15 Jan 2019 //
PHARMA TIMES
Genentech`s Perjeta(Pertuzumab) Receives Approval in US
18 Dec 2018 //
FDA
NeuClone Announces its 6th Biosimilar Candidate Perjeta for use in Combination Therapy with Herceptin
18 Dec 2018 //
PR NEWSWIRE
SMC accepts four medicines for NHS use
11 Dec 2018 //
PHARMA TIMES
Chugai Pharma`s pertuzumab gets Japanese approval for HER2+ breast cancer
10 Oct 2018 //
PHARMABIZ
Genentech`s Biological Perjeta (Pertuzumab) Receives Approval in US
24 Sep 2018 //
FDA
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 Aug 2018 //
PHARMA TIMES
Roche’s MS drug Ocrevus earns blockbuster status a year after launch
31 Jul 2018 //
PHARMAPHORUM
Upbeat Roche bests rival Novartis as new drugs fuel growth
26 Jul 2018 //
REUTERS
Ocrevus, Roche`s `most successful launch,` crosses blockbuster line
26 Jul 2018 //
FIERCE PHARMA
Patients wait as Vertex, U.K. officials argue over Orkambi price
09 Jul 2018 //
FIERCE PHARMA
NICE dogs Roche`s Perjeta again
15 Jun 2018 //
FIERCE PHARMA
NICE rejects adjuvant use of Perjeta post-surgery
15 Jun 2018 //
PHARMA TIMES
Roche’s Perjeta combo approved in Europe for early breast cancer
05 Jun 2018 //
REUTERS
Zymeworks Announces Bi-Specific Antibody Collaboration with Celgene
21 Jan 2015 //
ZYMEWORKS
